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BACKGROUND AND OBJECTIVES: Cyclophosphamide plus total body irradiation (CYtBi) and oral busulfan 
plus cyclophosphamide (BuCY) are commonly used conditioning regimens prior to allogeneic hematopoietic 
stem cell transplantation (hsCt) in patients with leukemia. however, there is conflicting data on the superiority 
of one regimen over the other. our aim was to critically appraise and synthesize available evidence regarding 
the efficacy and safety of CYtBi compared to BuCY as a conditioning regimen. 
DESIGN AND SETTING: systematic review and meta-analysis of randomized, controlled trials (rCts) compar-
ing BuCY with CYtBi.
METHODS: We did a systematic search of the indexed medical literature using appropriate keywords to identify 
potentially relevant articles. the primary outcome of interest was efficacy measured by overall survival (os) and 
disease-free survival (Dfs). acute and late toxicity were secondary endpoints. meta-analysis was attempted only 
on rCts. a relative risk or risk ratio (rr) and 95% confidence interval (Ci) was calculated for each outcome in 
the meta-analysis.
RESULTS: fifteen non-randomized comparative studies involving 6280 patients were included in a narrative 
review without attempting a pooled analysis, in view of the potential for significant bias. outcome data from 
seven rCts involving 730 patients randomly assigned to either CYtBi or BuCY was pooled using meta-analytic 
methods. CYtBi was associated with a modest but non-significant reduction in all cause mortality (rr=0.82, 
95%Ci: 0.64-1.05; P=.12) and relapse of leukemia (rr=0.89, 95%Ci: 0.72-1.10; P=.28). transplant-related mor-
tality (trm) was significantly lesser with CYtBi compared to oral BuCY (rr-0.53, 95%Ci: 0.31-0.90; P=.02). 
the cumulative incidence of major complications was not significantly different between the two regimens, but 
specific complications varied according to the conditioning regimen. tBi-based regimens were associated with 
more severe late effects on growth and development in children. 
CONCLUSION: this analysis represents the largest comparative analyses of CYtBi with BuCY as a conditioning 
regimen prior to hsCt in the indexed medical literature. Conditioning regimen and disease (type and setting) 
can significantly affect outcomes. trm is significantly lesser with CYtBi, but this does not translate into a sig-
nificant survival benefit. there remain valid concerns regarding the late effects of tBi, particularly in children. 
although not overly superior, the weight of evidence favors CYtBi over BuCY as a first choice-conditioning 
regimen in patients with leukemia. 
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Hematopoetic stem cell transplantation (HSCT) is being increasingly utilized world-wide in contemporary hematology-oncol-
ogy practice.1 One of the commonest indications for 
allogeneic HSCT is leukemia,1,2 in an upfront setting 
for primary refractory disease, after first remission for 
high-risk disease, or at relapse after achieving another 
remission with high-dose salvage chemotherapy. The 
anti-neoplastic activity of allogeneic HSCT is mediat-
ed by the high-intensity of the conditioning regimen as 
well as the immune-mediated graft-versus-disease reac-
tion.2,3 The two most commonly used conditioning reg-
imens have been cyclophosphamide (CY) plus fraction-
ated total body irradiation (TBI), known as CYTBI4,5 
or oral busulfan (BU) plus cyclophosphamide, known 
as BUCY.6,7 There are inherent advantages8 of TBI-
based regimens such as adequate treatment of sanctu-
ary sites, dose deposition regardless of vascular supply, 
no cross-resistance with chemotherapy, and a potential 
for shielding or boosting of specific sites. However, 
there have been concerns regarding late sequelae includ-
ing cataracts, second malignancies, growth retardation, 
neuro-endocrine and neuro-psychologic dysfunction, 
particularly in children9 prompting the use of chemo-
therapy-alone regimens as an alternative to TBI-based 
conditioning. There is inconclusive evidence on the su-
periority of one regimen over the other, both in terms 
of efficacy as well as toxicity. Retrospective comparative 
studies including reports from international transplant 
registries, prospective randomized controlled trials 
(RCTs), as well as previously attempted pooled analy-
ses have yielded conflicting results and the most optimal 
conditioning regimen prior to transplantation in leuke-
mia remains to be defined. The objective of this system-
atic review was to critically appraise all the available evi-
dence and attempt a meta-analysis of RCTs comparing 
BUCY with CYTBI as a conditioning regimen prior to 
HSCT in patients with leukemia.
METHODS
Inclusion and exclusion criteria for study selection
All reports comparing BUCY with CYTBI as full-in-
tensity (myeloablative) conditioning regimens prior to 
HSCT in patients with acute lymphoblastic leukemia 
(ALL), acute myeloid leukemia (AML) or chronic 
myeloid leukemia (CML) were considered eligible for 
inclusion. Non-randomized comparisons from retro-
spective studies and international transplant registries 
were also included. All reports from clinical trials ran-
domly assigning patients to either TBI-based regimen 
or BUCY, and published as full text were considered for 
pooling in the meta-analysis. Trials comparing different 
doses of TBI or different chemotherapy regimens only 
were not considered for inclusion. Studies on autoim-
mune diseases and non-myeloablative or reduced-in-
tensity conditioning were also not considered. 
Literature search strategy
A systematic search of PubMed was done from 1965 
until June 2010 to identify all relevant and appropriate 
studies. Different keywords including Medical Subject 
Heading (MeSH) terms were combined using Boolean 
operations ‘AND’ and ‘OR’, such as “total body irradia-
tion” OR “whole-body irradiation” [Mesh] AND (“bone 
marrow transplantation” [Mesh] OR “peripheral blood 
stem cell transplantation” [Mesh]) OR “transplantation” 
[MeSH] OR “leukemia” [Mesh] AND “busulfan” AND 
“cyclophosphamide”. The Cochrane Library including 
the Cochrane Central Register of Controlled Trials and 
the Cochrane Database of Systematic Reviews was also 
searched to identify potentially relevant trials and re-
view articles respectively. Cross-references from selected 
articles were also used for retrieving relevant studies.
Outcome measures
The primary outcome of interest was efficacy as mea-
sured by overall survival (OS) and disease-free survival 
(DFS) (leukemia-free survival). Secondary outcomes 
included toxicity parameters like transplant-related 
mortality (TRM), acute graft-versus-host-disease 
(aGVHD), chronic GVHD (cGVHD), interstitial 
pneumonitis (IP), and veno-occlusive disease (VOD). 
Data extraction for the purpose of the meta-analysis 
was done by two reviewers jointly and later verified by 
the third reviewer independently. Any discrepancy was 
resolved by consensus. 
Statistical methods
Non-randomized comparative studies were restricted 
to a narrative systematic review, as it was considered 
inappropriate to pool them for attempting a meta-
analysis due to potential imbalances and biases inher-
ent to retrospective analyses. Outcome data from all 
included RCTs were pooled for meta-analysis. Meta-
analysis for any outcome of interest was attempted only 
if relevant data could be extracted from five or more 
trials. All meta-analyses were performed using the 
random effects model (assuming the existence of het-
erogeneity) to provide a more conservative yet robust 
estimate of effect. Review Manager (RevMan version 
5.0, Copenhagen, The Nordic Cochrane Centre, The 
Cochrane Collaboration 2008) was used for perform-
ing the meta-analyses. Relative risk or risk ratio (RR) 
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and 95% confidence interval (CI) were calculated for 
each outcome and presented as forest plots after pool-
ing. The pooled RR, symbolized by a solid diamond at 
the bottom of the forest plot (the width of which rep-
resents the 95%CI) is the best estimate of the pooled 
outcome. Sensitivity or influence analysis was carried 
out to assess the influence of each study on the overall 
summary effect. 
RESULTS 
Figure 1 is a flowchart showing selection and exclu-
sion of studies using the pre-specified search strategy. 
An unrestricted search of the indexed medical literature 
yielded a total of 2714 potential abstracts. Of these, 201 
abstracts were considered for further review based on 
pre-specified eligibility criteria. The search was further 
refined to yield 103 abstracts by limiting to ‘controlled 
clinical trials’, and the ‘English’ language. After a review 
of full-text articles of all eligible abstracts, 15 non-ran-
domized comparative studies and 11 RCTs comparing 
a TBI-based conditioning regimen with BUCY were 
identified. One randomized trial10 comparing two doses 
of melphalan with or without TBI in multiple myeloma 
was excluded. All 15 non-randomized studies involving 
6280 patients were included, but restricted to a narra-
tive systematic review without pooled analysis. Amongst 
the ten included articles identified as randomized trials, 
three were updates of previous RCTs and not separate 
trials. However, data extraction was done from both the 
original publication as well as the updated publication 
for the purpose of the meta-analysis. Thus seven trials 
reported in ten publications including three long-term 
mature updated results involving a total of 730 patients 
randomly comparing CYTBI with BUCY comprised 
the dataset for the meta-analysis. 
Review of non-randomized comparative studies
The CYTBI regimen was first used successfully as a 
conditioning regimen in the 1970s.4,5 However, due 
to concerns regarding long-term sequelae, non-TBI 
regimens were investigated by substituting it with oral 
busulfan6,7 in an attempt to reduce toxicity. There have 
been several retrospective comparisons (Table 1) of 
these two conditioning regimens, both in terms of effi-
cacy11-15 and safety including late toxicity.16-20 
Comparison of efficacy
Michel et al11 analyzed the French experience with 
BUCY as a conditioning regimen used as either 
BUCY120 (120 mg cyclophosphamide) (n=23) or 
BUCY200 (120 mg cyclophosphamide) (n=19) and 
compared it with CYTBI (n=32) in children with AML 
Abstracts identified through initial systematic search of indexed medical literature
(n=2714)
Abstracts considered for further detailed review based on pre=specified eligibility criteria
(n=201)
Full-text review of studies potentially eligible for inclusion in review
(n=10)
Abstracts not considered
(n=251)
(non-comparative studies, non-relevant reports, reviews, editorials, etc.)
Abstracts not eligible
(n=98)
(non-english abstracts, studies on autoimmune diseases, solid tumors, 
lymphoma, myeloma, etc.)
Studies excluded after review
(n=78)
(Studies using alternative conditioning, reduced-imensity, non-myleoablative 
conditioning, comparing different doses of TBi, non-extractable data, etc.)
non-randomized comparisons included in narrative review
(n=15)
       •   efficacy studies (n=5)
       •   Late toxicity studies (n=5)
       •   resgistry database analysis (n-5)
randomized Controlled Trials (rCTs) pooled for meta-analysis
(n=10)
        •   rCTs (n=7)
        •   updates of rCTs (n=)  
Figure 1. Flowchart of study selection in the systematic review and meta-analysis
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in first complete remission. The probability of relapse 
was significantly higher in BUCY120 (54%), but was 
similar in the BUCY200 (13%) and TBI (10%) arms. 
The 3-year event-free survival (EFS) was 46% (95%CI: 
22-70%), 82% (95%CI: 64-100%), and 80% (95%CI: 
66-94%), respectively, in the three groups. Multivariate 
analysis identified conditioning with BUCY120 and 
delayed transplantation (>120 days from diagnosis) as 
independent negative prognostic factors. 
Granados et al12 retrospectively compared outcomes 
in 156 consecutive patients with ALL conditioned with 
CYTBI (n=114) or BUCY (n=42). At a median fol-
low-up of 6 years, EFS was 43% (95%CI: 35-51%) in 
the CYTBI versus 22% (95%CI: 10-34%) in the BUCY 
cohort (P=.01). TRM was 22% and 17% in the BUCY 
and CYTBI groups, respectively (P=.24). The actuarial 
Table 1. non-randomized comparative studies of efficacy and safety of CyTBi compared with BuCy as a conditioning regimen.
Author, year (reference) CYTBI (N) BUCY (N) Diagnosis
Age range 
(median, 
y)   
Median
follow-up
(y)
Conclusions
Comparison of efficacy
   michel, 199411 2 42 AmL ≤16  BuCy120 inferior to BuCy200 & CyTBi
   granados, 200012 114 42 ALL 1-59 6 CyTBi better than BuCy for ALL
   Kim, 20011   26 27 CmL 17-50 (2) .5 BuCy acceptable alternative to CyTBi
   Kroger, 200114 25 25 CmL 16-52 (6)  Similar efficacy, but, higher toxicity with BuCy
   Lahteenmaki, 200415 26 18 ALL, AmL, misc <7 5 CyTBi better for high risk groups
Comparison of late 
toxicity
   Wingard, 199216 2 24 ALL, AmL 1-12 (6.5) 2 growth impairment similar in both regimens
   Hartsell, 199517 79 65 ALL, AmL, misc 2-57 (28) 4.4
cgVHd, prior bleomycin use had 
pulmonary toxicity
   michel, 199718 19 26 AmL 1-16 (8.5) 5.9 Late toxicities lesser with BuCy
   Holmstrom, 200219 21 24 AmL, ALL, CmL ≤17 5
Higher incidence (95%) of cataract 
in TBi
   Smedler, 200820 12 10 ALL, AmL, CmL 0.4-.6 (2) 6.5
Favorable neuropsychological 
profile with BuCy
n= number of patients, y= years
Table 2. Comparative studies of CyTBi with BuCy from international transplant registries.
Author, year 
(reference) CYTBI (N) BUCY (N) Diagnosis
Age range 
(median, y) 
Median 
follow-up 
(y)
Conclusions
ringden,199621 921 921 ALL, AmL All ages 2 CyTBi has better outcomes in medium risk ALL
davies, 200022 451 176 ALL 1-20 (12)  CyTBi is the superior regimen in ALL
Litzow, 20022 200 81 AmL 20-57 (5) 5 CyTBi reduces relapse without improving survival
Kanda, 200524 714 24 ALL, AmL, CmL  (16-6) 5
CyTBi first choice regimen in 
unrelated HSCT 
uberti, 201025 1275 18 AmL, CmL 1-58 (7) 8 equivalent efficacy & safety of both regimens
n= number of patients, y= years
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probability of relapse at 3-years was significantly higher 
in the BUCY group (71% versus 47%; P=.01), leading 
to the conclusion that TBI-based regimen should re-
main the standard preparative method in ALL. 
In a comparative analysis of the two regimens,13 53 
patients with CML treated with HLA-identical sibling 
donor transplants were included. TRM was similar in 
both groups (19% in BUCY versus 12% in CYTBI). 
Grade II–IV acute GVHD was 9% in BUCY as 
compared to 52% with CYTBI. The overall incidence 
of chronic GVHD was similar (BUCY, 50% versus 
CYTBI, 52%). In patients with chronic phase, 5-year 
OS was 73% in the BUCY group compared with 87% 
in the CYTBI group (statistically non-significant). DFS 
was 75% in BUCY and 59% in the CYTBI group (statis-
tically non-significant). The actuarial 5-year relapse rate 
was 15% after BUCY versus 34% after CYTBI (P=.46), 
suggesting that BUCY may be an acceptable alternative 
for patients with CML during human leukocyte antigen 
(HLA)-identical sibling allogeneic HSCT.
In another study14 of 50 patients with CML treated 
with unrelated stem cell transplantation using either 
BUCY or CYTBI, there were no significant differ-
ences in efficacy between the two regimens. The inci-
dence of grade II–IV GVHD was similar between the 
two groups (CYTBI, 40% and BUCY, 36%). The inci-
dence of cGVHD at 1 year was higher in the BUCY 
group (65% versus 30%; P=.02). Hepatic toxicity and 
hemorrhagic cystitis was also significantly higher with 
BUCY. There were seven relapses in CYTBI group 
compared to no relapse in BUCY after a median fol-
low up of 44 and 15 months, respectively. The estimat-
ed 3-year OS was 72% (95%CI: 55-98%) for CYTBI 
and 70% (95%CI: 52-98%) for BUCY (P=.7). Similar 
values for DFS were 58% (95%CI: 39-77%) and 70% 
(95%CI: 51-89%) respectively (P=.7), suggesting that 
the anti-leukemic activity of BUCY may be compa-
rable to CYTBI in unrelated stem cell transplantation 
for CML. 
Lahteenmaki and colleagues15 retrospectively evalu-
ated 44 children (<7 years) with hematologic malig-
nancies conditioned with either single fraction TBI 
(n=26) plus cyclophosphamide or BUCY (n=18). 
The rates of neutrophil engraftment, aGVHD and 
cGVHD were similar in the two arms. The 5-year ac-
tuarial survival was 43.3% (95%CI: 23.3-63.3%) and 
33.3% (95%CI: 7.9-58.7%) in the CYTBI and BUCY 
groups, respectively (P=.6). However, CYTBI was as-
sociated with a trend towards improved survival in the 
high-risk subgroup. Long-term overall survival was sig-
nificantly better with the TBI-based regimen in ALL, 
while BUCY was superior for myeloid malignancies. 
Endocrinopathies, cognitive dysfunction and cataract 
were seen commonly in TBI whereas behavioral prob-
lems, deafness, seizures, and developmental problems 
were associated with BUCY.
Author, year 
(reference) CYTBI (N) BUCY (N) Diagnosis
Age range 
(median, y) 
Median
Follow-up 
(y)
Conclusions
Blaise, 199226
Blaise†, 200127 50 51 AmL 2 (mean)
2
10.8
BuCy inferior to CyTBi
Confirms inferiority of BuCy
Blume, 19928 61 61 AmL, ALL, CmL 2-48 2.5
no difference in safety or efficacy 
of both regimens
Clift, 199429
Clift†, 19990 69 7 CmL 6-55 (7)
1 
(minimum)
7.7
BuCy compares favorably to CyTBi 
in CmL
Confirms better tolerability, similar 
efficacy of BuCy
ringden, 19941
ringden†, 19992 79 88 CmL 1-55 (4)
2.1
7
CyTBi regimen of choice, for high-
risk disease
Confirms higher late toxicity, lower 
efficacy of BuCy
dusenbery, 1995 18 17 AmL 1.6-56 2.6 CyTBi equivalent or better than BuCy
devergie, 19954 55 65 CmL 10-54 (6) .5 Similar outcomes with both regimens
Bunin, 2005 22 21 ALL 0.5-20 (8) .6 BuCy is inferior to CyTBi in pediatric ALL
† long-term update of previous trial 
Table 3. randomized controlled trials comparing CyTBi with BuCy as conditioning regimen in leukemia. 
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Comparison of late toxicities
Wingard and colleagues16 assessed growth during the 
first 2 years after transplant in children (age <12 years) 
treated with either BUCY (n=24) or CYTBI (n=23). 
Prior to transplant, their median height was 0.2 stan-
dard deviation (SD) below age- and sex-adjusted means 
(range: -2.5 to +3.0). Pre-transplant heights were com-
parable in the BUCY and CYTBI groups. Following 
transplant, median 1-and 2-year heights were 0.7 and 
0.9 SD below normal, respectively. Growth rates were 
2.2 SD and 1.4 SD below normal during the first and 
second years respectively. There was no significant differ-
ence in the growth rates between BUCY versus CYTBI 
[-2.5 versus -1.7 SD during the first year (P=.19) and 
-1.5 versus -1.1 SD during the second year (P=.61)].
Hartsell et al17 retrospectively compared pulmonary 
complications in patients conditioned with CYTBI 
(n=79) and BUCY (n=65). The 1-year actuarial pul-
monary complication rate was similar between the two 
groups (32.9% versus 29.5%; P=.61). The incidence of 
acute pulmonary complications such as acute respirato-
ry distress syndrome, infective lobar pneumonia, inter-
stitial pneumonia, or diffuse pulmonary infiltrates was 
similar between the two groups. However, late pulmo-
nary events (occurring >45 days after transplant) such 
as interstitial pneumonia, obliterative bronchitis, lobar 
pneumonia, or asthma were significantly higher in the 
CYTBI compared to BUCY (n=15 versus 4; P=.04). 
Pulmonary complications were significantly associated 
with GVHD and prior bleomycin use. 
Michel and colleagues18 compared late effects of 
BUCY (n=26) and CYTBI (n=19) in a French cohort 
of AML patients transplanted in first remission and 
followed for a mean of 5.9 years. The mean cumulative 
changes in height SD score was -0.86 at 3-years and -
1.56 at 5-years in the TBI group, which was inferior to 
-0.05 and -0.17 in the BUCY group (P<.01) at similar 
time points. The 6-year probability of hypothyroidism 
was 9% (95%CI: 1-17%) with BUCY compared to 43% 
(95%CI: 28-58%) with TBI (P<.02). The 6-year prob-
ability of cataract was 70% (95%CI: 57-83%) with TBI, 
while no child in the BUCY group developed cataract 
suggesting that BUCY has a better late toxicity profile 
as a cytoreductive conditioning regimen. 
Researchers at the Karolinska Institute followed up 
children treated with BUCY (n=24) or CYTBI (n=21) 
conditioning for the development of lens opacities with 
annual ophthalmic evaluations for 10 years.19 Cataracts 
developed in 20/21 (95%) children conditioned with 
TBI-based regimens as compared to only 5/24 (21%) 
children conditioned with busulphan. There was no 
relationship between cataract development and age at 
transplant or treatment with corticosteroids. 
Long-term neuro-psychological outcomes were 
compared in very young children (age <3.6 years) treat-
ed with BUCY (n=10) or CYTBI (n=12), with exten-
sive assessments done at an average of 6.5 years post-
transplant.20 The BUCY group performed at age level 
on verbal measures, but tended to score below age level 
in the executive and visuo-spatial domains (P<.01). In 
comparison, children treated with CYTBI had more 
pervasive neuro-psychological impairments, including 
motor deficits (P<.01) and varying degrees of percep-
tual (P<.05), executive and cognitive (P<.05) problems 
leading to the conclusion that BUCY was more favor-
able for neuro-psychological development for children 
transplanted at a very young age. 
Analyses of registry database 
The HSCT fraternity has set up several international 
registries, namely the European Cooperative Group 
Bone Marrow Transplantation (EBMT) registry, the 
International Bone Marrow Transplantation Registry 
(IBMTR), and the Centre for International Blood 
and Marrow Transplant Research (CIBMTR), where 
participating centres voluntarily contribute detailed 
data on demography, disease characteristics, transplant 
characteristics, and outcomes, both for autologous as 
well as allogeneic transplants (Table 2). The first such 
analysis reported by Ringden et al21 compared the out-
come of patients in the EBMT database transplanted 
for acute leukemia between 1987 until 1994, who had 
been treated with either BUCY or CYTBI as a condi-
tioning regimen. Patients were matched for age, type of 
transplant (autologous versus allogeneic), type of leu-
kemia (myeloid versus lymphoid), disease status (early 
versus intermediate), prevention of GVHD, and year of 
transplant. A total of 1842 patients (921 in each arm) 
were included in this matched-pair analysis. In patients 
treated with autologous transplant (530 matched pairs) 
in early stage acute leukemias and intermediate stage 
AML, transplant-related deaths, relapse incidence, and 
leukemia-free survival did not differ significantly be-
tween the two groups. However, in patients with inter-
mediate stage ALL, the probability of relapse was signif-
icantly higher in BUCY (82%, 95%CI: 77-87% versus 
62%, 95%CI: 56-68%; P=.002) compared to CYTBI. 
Similarly, the 2-year leukemia-free survival was signifi-
cantly better with CYTBI (34%, 95%CI: 28-40% ver-
sus 14%, 95%CI: 10-18%; P=.002). In patients treated 
with allogeneic transplant from HLA-identical siblings 
(391 matched pairs), the relapse incidence, TRM and 
leukemia-free survival was similar in both groups with 
no significant differences. BUCY was associated with 
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higher incidence of VOD and hemorrhagic cystitis. 
Outcomes data on children (age <20 years) with 
ALL treated with HLA-identical sibling transplants 
between 1988 and 1995 using either BUCY (n=176) 
or CYTBI (n=451) reported to the IBMTR were com-
pared retrospectively.22 Both groups were well balanced 
in terms of gender, immune phenotype, leukocyte count 
at diagnosis, chromosomal abnormalities, remission 
status and duration. With a median follow-up of 37 
months, the 3-year estimate of OS was 55% (95%CI: 
50-60%) in CYTBI and 40% (95%CI: 32-48%) in 
the BUCY group (P=.003). The 3-year probability of 
leukemia-free survival was 50% (95%CI: 45-55%) and 
35% (95%CI: 28-43%), respectively (P=.005). All-
cause mortality (RR-1.39; P=.17), TRM (RR-1.68; 
P=.12) and treatment failure (RR-1.42; P=.006) was 
significantly worse in the BUCY group on multivariate 
analysis leading to the conclusion that CYTBI was the 
superior conditioning regimen in HLA-identical sibling 
transplants in children with ALL. 
Litzow et al23 reported a similar comparison from 
the IBMTR database in patients with AML in first re-
mission treated with HLA-identical sibling transplants 
between 1988 and 1996 using either CYTBI (n=200) 
or BUCY (n=381). BUCY was associated with a high-
er incidence of hepatic veno-occlusive disease (VOD) 
(13% versus 6%; P=.009). The risks of acute and 
chronic GVHD were similar between the two groups. 
The risk of relapse was higher in the BUCY group (RR- 
1.72, 95%CI: 1.05-2.81; P=.031). However, there were 
no significant differences in TRM, leukemia-free sur-
vival, and overall survival between the two groups. 
Kanda et al24 retrospectively compared outcomes 
in patients receiving transplantation from an unre-
lated donor between 1993 and 2002 registered in the 
Japan Marrow Donor Program. Standard dose CYTBI 
(n=714), intensified CYTBI (n=861), BUCY (n=243) 
and BUCY with total lymphoid irradiation (n=57) 
were compared using multivariate analysis. There were 
significant differences between the patient background 
characteristics at baseline in terms of age, diagnosis, risk-
category, and GVHD prophylaxis. Standard CYTBI 
was significantly better than BUCY with regards to in-
cidence of engraftment failure (OR-2.49; P=.046) and 
OS (RR-1.31; P=.50). Intensified CYTBI resulted in 
inferior OS probably due to larger number of poor-risk 
patients. BUCY with total lymphoid irradiation im-
proved engraftment but increased non-relapse mortal-
ity. Secondary analysis of standard dose CYTBI with 
BUCY alone confirmed the inferiority of BUCY in 
terms of engraftment failure (OR-2.53, 95%CI: 1-6.39; 
P=.49) and overall survival (RR-1.32, 95%CI: 1-1.75; 
P=.53), leading to the conclusion that standard dose 
CYTBI remains the regimen of first-choice in patients 
with unrelated HSCT. 
The most recent comparative analysis25 of BUCY 
versus CYTBI in myeloid leukemia and myelodyspla-
sia included 1593 patients treated with T-replete unre-
lated marrow donor transplantation from 1991 to 1999 
and reported to the CIBMTR. The CYTBI group in-
cluded patients with standard-dose TBI (1000-1260 
cGy) or high-dose TBI (1320-1500 cGy). Neutrophil 
and platelet engraftment was better with standard-
dose CYTBI (n=420) compared to BUCY (n=318) 
or high-dose CYTBI (n=855). The cumulative inci-
dence of grades III-IV acute GVHD was similar in all 
three groups. At 6-months, the cumulative incidence of 
chronic GVHD was higher in the CYTBI-based regi-
mens compared to BUCY (35% versus 23%; P=.001), 
which lost significance over time. At 5-years, there was 
no significant difference (P=.779) in overall survival be-
tween standard-dose CYTBI (35%, 95%CI: 30-40%), 
high-dose CYTBI (32%, 95%CI: 28-36), and BUCY 
(33%, 95%CI: 30-36%). Similarly there was no differ-
ence in disease-free survival (P=.464) or TRM (P=.37) 
between the three groups. On univariate analysis, the 
cumulative incidence of relapse was significantly higher 
at 1-year in the high-dose CYTBI group compared to 
standard-dose CYTBI or BUCY (P<.001). However, 
there was no difference in the risk of relapse between 
the three groups (P=.155) on multivariate analysis. 
Meta-analysis of randomized controlled trials
Outcome data from seven randomized controlled trials 
(Table 3) reported in 10 publications26-35 (including 3 
updates) between 1992 and 2003 involving a total of 
730 patients randomly assigned to either CYTBI or 
BUCY were pooled for meta-analysis. Baseline charac-
teristics were well balanced in both arms in all these tri-
als, reducing the potential for bias. The median follow-
up though variable was generally robust across studies 
(ranging from 2 to 10.8 years). 
Overall survival and disease-free survival 
All RCTs provided data on overall survival and disease-
free survival. The 4-year survival rate was used to cal-
culate the number of events (deaths for overall survival 
and relapse of leukemia for disease-free survival) in 
each trial for both treatment groups. The use of CYTBI 
was associated with an 18% reduction in mortality at 4-
years (RR-0.82, 95%CI: 0.64-1.05; P=.12) compared 
to BUCY (Figure 2) that was not statistically signifi-
cant. CYTBI was also associated with a non-significant 
reduction (11%) in the risk of leukemia relapse (Figure 
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2) compared to the BUCY regimen (RR-0.89, 95%CI: 
0.72-1.10; P=.28). 
Transplant-related mortality 
Six RCTs reported on deaths directly attributable to the 
transplant-related complications. The use of CYTBI as 
a conditioning regimen was associated with a 47% re-
duction in the relative risk of transplant-deaths (Figure 
3) compared to BUCY regimen, that was statistically 
highly significant (RR-0.53, 95%CI: 0.31-0.90; P=.02). 
However, it may be pertinent to note that intravenous 
busulfan with its more predictable pharmacokinetics 
and better toxicity profile was not available at that time 
limiting these trials to its oral use. 
Acute and chronic GVHD 
Acute GVHD generally occurs within first 3 months of 
transplantation, while chronic GVHD occurs beyond 3-
months. Data on the incidence of acute as well as chronic 
GVHD could be extracted from 5 trials that were pooled 
for meta-analysis. A modest but non-significant increase 
in the incidence of grade II-IV aGVHD (Figure 4a) 
was seen with CYTBI compared to BUCY (RR-1.16, 
95%CI: 0.92-1.45; P=.22). However, the incidence of 
cGVHD was very similar (Figure 4b) in the two treat-
ment groups (RR-0.96, 95%CI: 0.77-1.20; P=.72). 
Other complications 
Interstitial pneumonitis, an inflammatory complication 
involving the lung post-transplant was reported in six 
trials. CYTBI was associated with a moderate, though, 
non-significant increase in the risk of clinically signifi-
cant pulmonary complications (Figure 5a) compared to 
BUCY (RR-1.22, 95%CI: 0.79-1.88; P=.37). In post-
transplant setting, VOD generally affects the hepatic si-
nusoidal vessels leading to progressive liver dysfunction. 
CYTBI was associated with a 64% relative risk reduc-
tion in the incidence of VOD of the liver as compared 
to BUCY (RR-0.36, 95%CI: 0.15-0.86; P=.02), that 
was highly statistically significant (Figure 5b). There 
was lack of extractable data from these randomized 
trials on other late complications such as the incidence 
of cataract, growth retardation, endocrine dysfunction, 
fertility impairment, and neuropsychological dysfunc-
tion to attempt pooled analysis. 
Sensitivity/influence analysis
Sensitivity analysis was also done for all outcome mea-
sures by dropping one study at a time to assess if any 
single study has a major influence on the overall sum-
mary effect. None of the studies seemed to influence the 
overall effect for any outcome. 
DISCUSSION 
The most optimal conditioning regimen prior to 
HSCT in patients with leukemia remains to be de-
fined.36 This analysis represents the largest systematic 
body of evidence involving over 7000 patients compar-
ing the efficacy and safety of two of the most commonly 
used conditioning regimens i.e. CYTBI and BUCY. 
There have been previous attempts at a systematic 
review and meta-analysis addressing the same issue. 
Hartman et al37 pooled individual study data from 5 
RCTs comparing CYTBI with BUCY and computed 
the odds ratio (OR) using the random effects model 
with overall survival, disease-free survival, and toxicities 
as endpoints. Although survival (both overall as well as 
DFS) was superior with TBI-based regimens (OR-1.4, 
95%CI: 0.9-2.2; P=.09 and OR-1.2, 95%CI: 0.7-2.1; 
P=.44, respectively), this difference was not statisti-
cally significant. However, a power analysis could not 
exclude a survival advantage for TBI-based regimens. 
A significantly greater incidence of VOD was associ-
ated with BUCY (OR-2.5, 95%CI: 1.2-5.2; P=.02). 
Other toxicities were similar between the two groups, 
supporting the notion that CYTBI was the better con-
ditioning regimen. Since then, two newer RCTs have 
been published and data from four trials included in 
the Hartman meta-analysis has been updated. In the 
update38 on patients in 4 randomized trials comparing 
BUCY with CYTBI, the projected 10-year overall sur-
vival was similar (65% and 63%, P=.73 respectively) for 
CML, but non-significantly inferior with BUCY (51% 
versus 63%, P=.068) for patients with AML. The inci-
dence of long-term complications, general health status, 
and return to work was similar between the two regi-
mens except for an increased risk of cataract in CYTBI 
and alopecia in BUCY. 
Recently, Shi-Xia and colleagues39 pooled data 
from all published comparative studies including 
retrospective and non-randomized comparisons. 
Eighteen reports involving 3172 patients were as-
sessed. For patients with ALL and AML, CYTBI 
regimen was associated with lower rates of relapse 
(OR-0.65, 95%CI: 0.22-1.88; P=.42 and OR-0.69, 
95%CI: 0.49-0.98; P=.04, respectively). However in 
patients with CML, the rate of leukemia relapse was 
significantly higher with CYTBI (OR-2.51, 95%CI: 
1.29-4.89; P=.007). CYTBI also resulted in better 
DFS for acute leukemia, with an OR of 1.93 (95%CI: 
1.42-2.64; P<.0001) for ALL and 1.49 (95%CI: 
1.01-2.20; P=.04) for AML. However, there was no 
significant difference between the two regimens in 
DFS for patients with CML (OR-0.93, 95%CI: 0.44-
1.98; P=.85). TRM was significantly improved with 
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Figure 2. Forest plot of overall survival (A) and disease-free survival (B). each study is represented by the point estimate of the risk 
ratio (square proportional to weight of the study) with 95%Ci. Summary pooled estimates with 95%Ci are shown as diamonds at the 
bottom of each figure. 
Figure 3. Significant relative reduction in the risk of transplant-related mortality with CyTBi as compared to BuCy regimen.
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CYTBI regardless of type of leukemia (OR-0.68, 
95%CI: 0.49-0.98; P=.02). The cumulative incidence 
of specific toxicities was somewhat dependent on the 
regimen. CYTBI was associated with higher rates of 
cataract (OR-12.69, 95%CI: 1.72-93.32; P=.01) in-
terstitial pneumonitis (OR-1.70, 95%CI: 1.24-2.32; 
P=.0009) and later growth/development problems 
(OR-5.85, 95%CI: 1.55-22.13; P=.009), whereas 
BUCY resulted in higher rates of VOD (OR-0.42, 
95%CI: 0.30-0.59; P<.00001) and hemorrhagic 
cystitis (OR-0.32, 95%CI: 0.19-0.54; P<.0001). 
Engraftment and GVHD (both acute and chronic) 
were similar between the two regimens. The authors 
concluded that conditioning regimens and type of leu-
kemia may affect outcomes in terms of DFS, relapse 
rates, TRM, and complications. However, there are 
several limitations to this report. The authors pooled 
data from retrospective non-randomized studies 
and quasi-randomized studies (prone to bias), with 
randomized controlled trials. There was significant 
heterogeneity between comparisons in terms of di-
agnoses, setting, prior treatment, age, source of stem 
cells, dose and fractionation of TBI, which could po-
tentially affect outcomes. 
Strengths and limitations of the present study
Our analysis represents the largest systematic body of 
evidence comparing the efficacy and safety of CYTBI 
with BUCY as a conditioning regimen prior to HSCT 
in patients with leukemia. Pooling of data for meta-
analysis was restricted only to randomized trials thereby 
reducing the potential for bias. However, several caveats 
and limitations remain that can potentially influence 
the results and interpretations. Transplant registries 
would have included patients from RCTs as well as in-
dividual comparative studies, resulting in them being 
counted more than once. Despite restricting the meta-
analysis to RCTs, significant heterogeneity was present 
in most comparisons. The total number of patients in 
the pooled analysis was also limited (730 patients) and 
not enough to draw robust conclusions. Several changes 
in the practice of transplantation have occurred over the 
last two decades, ushering in newer paradigms. Non-
myeloablative conditioning regimens are being increas-
Figure 4. Forest plot of acute gVHd (A) and chronic gVHd (B) showing no significant differences between CyTBi and BuCy
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ingly used in allogeneic HSCT with impressive and 
encouraging results.40 Peripheral blood stem cell trans-
plantation has largely superseded bone marrow as the 
source of stem cells.41 Intravenous busulfan with more 
predictable pharmacokinetics (with individualized dos-
ing), which reduces the risk of VOD by avoiding first-
pass metabolism in the liver has a better toxicity profile 
than oral busulfan and is being used more commonly in 
BUCY regimen.42,43 Newer techniques of total marrow 
irradiation with significantly reduced toxicity44 have 
been reported, that can be a suitable alternative to the 
standard TBI technique. Some of the recent improve-
ments in outcomes can be partially attributed to better 
supportive care45 with the use of newer antimicrobi-
als, improved GVHD prophylaxis, and refinements in 
methodology to identify and modify immune response. 
None of studies included in this systematic review and 
meta-analysis involved any of these newer paradigms. 
Whether the superiority of one regimen over the other 
will still be relevant in contemporary oncologic practice 
remains uncertain. 
The present analysis that includes all of these trials 
and their updates confirms the advantage of CYTBI 
over BUCY using modern meta-analytic methods, 
and can be considered the most robust evidence to 
date. Based on the above, it may be difficult to arrive 
at a definitive conclusion on the superiority of CYTBI 
over BUCY due to the lack of a large randomized con-
trolled trial. However, given the expected magnitude 
of benefit, more than 1000 patients would need to be 
enrolled in such a trial to detect a clinically meaning-
ful difference in survival, which is highly unlikely to 
happen. 
Conclusion
This analysis represents the largest comparison of 
CYTBI with BUCY as a conditioning regimen prior 
to HSCT in patients with leukemia that includes 
retrospective non-randomized studies, matched-pair 
analyses, as well as randomized clinical trials. High-
quality evidence from seven prospective RCTs was 
pooled together in a meta-analysis for evaluating their 
Figure 5. meta-analysis of interstitial pneumonitis (A) and VOd (B). note the increased relative risk of lung complications with CyTBi, 
but decreased risk of VOd as compared to BuCy
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relative efficacy and safety. TRM is significantly lesser 
with CYTBI compared to BUCY (oral busulfan), but 
this does not translate into a significant overall sur-
vival benefit. There remain valid concerns regarding 
the late sequelae of TBI, particularly in children. The 
cumulative incidence of major complications is not 
significantly different between the two groups; how-
ever, specific complications may vary according to the 
regimen. Although not outrightly superior, the weight 
of evidence favors CYTBI over BUCY as a first-choice 
conditioning regimen. 
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